The Critical Care Cardiology Education Summit (CCCES) 2024 is coming up, and The CardioNerds conference scholars will be on hand to cover the event. In this exclusive interview, Rachel Goodman, MD, a cardiology fellow at Tufts Medicine, and Yoav Karpenshif, MD, an assistant professor of cardiovascular medicine at the University of Pennsylvania, sit down with 2 luminaries in the field.
Advertisement
Capecitabine was compared with XELOX and fluorouracil plus cisplatin.
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
A study evaluated a digital cognitive-physical intervention as a therapeutic option for children with ADHD.
A recent study found that patients with severe asthma experienced “meaningful” improvements in asthma-related QoL.
It was critical to offer the screening program because most veterans with lung cancer are diagnosed at stage III or IV.
A study presented at ATS 2024 shed light on the outcomes of patients with cannabis use disorder and lung cancer.
People with poor sleep and high genetic risk have a significantly higher risk of developing digestive diseases.
The treatment is the first and only bispecific T-cell engager therapy for advanced SCLC.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Capecitabine was compared with XELOX and fluorouracil plus cisplatin.
Dr. Kim provides an overview of the FDA approval of tislelizumab for the treatment of advanced, metastatic esophageal cancer.
Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.
Rectal gastrointestinal stromal tumors are rare, making up only 0.1% of all rectal neoplasms and about 5.0% of all GISTs.
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
Dr. Yarchoan details neoantigen-specific T cell responses assessed in the study.
The Latest From Heme Today
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
